{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:48:45Z","timestamp":1782200925693,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013072","name":"Major Science and Technology Project of Hainan Province","doi-asserted-by":"publisher","award":["2022YZ034016"],"award-info":[{"award-number":["2022YZ034016"]}],"id":[{"id":"10.13039\/501100013072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502704"],"award-info":[{"award-number":["2022YFC2502704"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470211"],"award-info":[{"award-number":["82470211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2021GGA018"],"award-info":[{"award-number":["2021GGA018"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023J01694"],"award-info":[{"award-number":["2023J01694"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcyt.2026.102075","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:06:10Z","timestamp":1769713570000},"page":"102075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Etoposide\u202f+\u202fcytarabine plus granulocyte colony-stimulating factor mitigates daratumumab-associated impairment on stem cell mobilization in newly diagnosed multiple myeloma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-6535","authenticated-orcid":false,"given":"Zhijuan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nainong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcyt.2026.102075_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcyt.2026.102075_bib0002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102075_bib0003","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 Trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2026.102075_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102075_bib0006","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0007","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102075_bib0008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102075_bib0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jca.21556","article-title":"Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"33","author":"Moreb","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jcyt.2026.102075_bib0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/bmt.2014.322","article-title":"Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation","volume":"50","author":"Brioli","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102075_bib0011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-024-01165-w","article-title":"Optimal infused CD34(+) cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102075_bib0012","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","article-title":"Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy","volume":"25","author":"Cavallo","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102075_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-018-0119-4","article-title":"Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth","volume":"7","author":"Ma","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0014","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102075_bib0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjh.19141","article-title":"Insight into the mechanism of CD34(+) cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy","volume":"204","author":"Venglar","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0016","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41409-024-02260-z","article-title":"Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group","volume":"59","author":"Fazio","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102075_bib0017","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab\u202f+\u202fbortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102075_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41409-024-02432-x","article-title":"Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor","volume":"60","author":"Bertuglia","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102075_bib0019","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s00277-025-06372-4","article-title":"Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma","volume":"104","author":"Kwon","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0020","first-page":"328","article-title":"Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients","volume":"22","author":"Zappaterra","year":"2024","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jcyt.2026.102075_bib0021","article-title":"High efficacy of stem cell mobilization with etoposide+cytarabine plus G-CSF in patients with multiple myeloma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0022","article-title":"Efficacy and safety of stem cell mobilization with etoposide +cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0023","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","article-title":"Advances in stem cell mobilization","volume":"28","author":"Hopman","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.jcyt.2026.102075_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ph17070944","article-title":"Impact of Anti-CD38 monoclonal antibody therapy on CD34+ hematopoietic stem cell mobilization, collection, and engraftment in multiple myeloma patients\u2014a systematic review","volume":"17","author":"Bigi","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jcyt.2026.102075_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101854","article-title":"Daratumumab during myeloma induction therapy is associated with impaired stem cell mobilization and prolonged post-transplant hematologic recovery","volume":"16","author":"Mehl","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2026.102075_bib0027","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN Trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102075_bib0028","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3324\/haematol.2022.281610","article-title":"Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients","volume":"108","author":"Lemonakis","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102075_bib0029","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"Suppl.1","key":"10.1016\/j.jcyt.2026.102075_bib0030","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2023-185907","volume":"142","author":"Cavallaro","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102075_bib0031","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1097\/CM9.0000000000002475","article-title":"Efficacy and safety of tandem autologous stem cell transplantation in multiple myeloma: a retrospective single-center analysis","volume":"136","author":"Wu","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jcyt.2026.102075_bib0032","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0033","first-page":"791","article-title":"Impact of daratumumab\/bortezomib\/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience","volume":"110","author":"Porrazzo","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102075_bib0034","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0035","doi-asserted-by":"crossref","first-page":"340.e1","DOI":"10.1016\/j.jtct.2023.02.013","article-title":"Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real-world experience","volume":"29","author":"Thurlapati","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102075_bib0036","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"64","author":"Eleutherakis Papaiakovou","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2026.102075_bib0037","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/ajh.25654","article-title":"Delayed neutrophil engraftment in patients receiving daratumumab as part of their first induction regimen for multiple myeloma","volume":"95","author":"Al Saleh","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2026.102075_bib0038","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bbmt.2010.11.021","article-title":"Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma","volume":"17","author":"Stiff","year":"2011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:16:43Z","timestamp":1782199003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1465324926000290"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102075","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etoposide\u202f+\u202fcytarabine plus granulocyte colony-stimulating factor mitigates daratumumab-associated impairment on stem cell mobilization in newly diagnosed multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102075"}}